Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
New York esophageal squamous cell carcinoma 1 peptide–Major Histocompatibility Complex class II complex (NY-ESO-1/MHC II)
- Target
- NY-ESO-1/MHC II
- Molecular classification
- Antigen-MHC complex, Protein complex
01
Overview
- Other names
- NY-ESO-1/HLA-DPB1*04:01 complexNY-ESO-1/HLA-DR complexCTAG1B/MHC II complexCancer/testis antigen 1B peptide–MHC II complexNY-ESO-1/HLA-DPB1*04:02 complex
02
Mechanism of action
T-cell receptor (TCR) mediated recognition of the NY-ESO-1 peptide presented by MHC class II molecules, leading to the activation of CD4+ T cells, secretion of Th1 cytokines (e.g., IFN-gamma), and enhancement of the overall anti-tumor immune response [3, 5].
03
Biological functions
Antigen presentationImmune responseT cell activationCD4+ T cell stimulation
04
Disease associations
CancerMelanomaSynovial sarcomaOvarian cancerMultiple myelomaNon-small cell lung cancer
05
Safety considerations
Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity}
06
Interacting drugs
GSK3845097
1 more in the full profile.
07
Biomarkers
NY-ESO-1 protein expression (IHC)CTAG1B mRNA expression (RT-PCR)HLA-DPB1*04:01 allele positivityHLA-DRB1*01:01 allele positivity
Beyond the preview
Go deeper on New York esophageal squamous cell carcinoma 1 peptide–Major Histocompatibility Complex class II complex (NY-ESO-1/MHC II).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on New York esophageal squamous cell carcinoma 1 peptide–Major Histocompatibility Complex class II complex (NY-ESO-1/MHC II).